Microbiome Gut Brain Axis In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The microbiome-gut-brain axis represents a critical bidirectional communication network linking the intestinal microbiota with the central nervous system. This pathway plays a significant role in neurodegeneration through multiple mechanisms including neural, endocrine, immune, and metabolic pathways.
flowchart TD
A[Gut Microbiota] --> B[SCFA Production] -->
A --> C[Secondary Bile Acids] -->
A --> D[Tryptophan Metabolites] -->
A --> E[Neural Pathways] -->
A --> F[Immune Modulation] -->
B --> G[Butyrate - Anti-inflammatory] -->
B --> H[Propionate - Glucose Metabolism] -->
B --> I[Acetate - Lipid Metabolism] -->
G --> J[HDAC Inhibition] -->
G --> K[Barrier Integrity] -->
H --> L[mTOR Signaling] -->
I --> M[Energy Homeostasis] -->
C --> N[FXR/TGR5 Signaling] -->
C --> O[Neurosteroid Synthesis] -->
D --> P[Serotonin Precursors] -->
D --> Q[Kynurenine Pathway)
D --> R[Indole Derivatives] -->
E --> S[Vagus Nerve Signaling] -->
E --> T[Enteric Nervous System] -->
F --> U[Systemic Inflammation] -->
F --> V[Microglial Activation] -->
J --> W[Gene Expression Regulation] -->
K --> X[Blood-Brain Barrier Integrity] -->
S --> Y[Brainstem Nuclei] -->
T --> Z[Hypothalamic Regulation] -->
U --> AA[Neuroinflammation)
V --> AB[Tau Pathology)
AA --> AD[Alzheimer's Disease)
AA --> AE[Parkinson's Disease)
AA --> AF[ALS)
AB --> AD
AE --> AG[Alpha-Synuclein Aggregation] -->
AG --> AE
| Molecule |
Function |
Disease Association |
| SCFAs |
Short-chain fatty acids - butyrate, propionate, acetate |
Anti-inflammatory, barrier protection |
| LPS |
Lipopolysaccharide - endotoxin from Gram-negative bacteria |
Neuroinflammation, BBB disruption |
| Bile Acids |
Primary/secondary bile acids via FXR/TGR5 |
Neuroprotection, dopamine modulation |
| Tryptophan Metabolites |
Serotonin, kynurenine, indoles |
Mood, neurotoxicity |
| Vagus Nerve |
Neural gut-brain communication |
α-Syn propagation in PD |
| GABA |
γ-Aminobutyric acid production |
Anxiety, sedation |
| Cytokines |
IL-6, TNF-α, IL-1β |
Systemic inflammation |
Gut bacteria influence Aβ aggregation through:
- Curli fiber formation: Certain bacteria produce curli that cross-seed amyloid formation
- LPS-induced inflammation: Promotes amyloid deposition in brain
- SCFA deficiency: Reduced butyrate leads to increased Aβ accumulation
Dysbiosis (microbial imbalance) increases:
- Systemic IL-6, TNF-α, IL-1β
- Microglial activation and proliferation
- Pro-inflammatory T cell infiltration
- Gut permeability → "leaky gut" → bacterial translocation
- Blood-brain barrier disruption
- Reduced tight junction proteins (claudin-5, occludin)
Vagus nerve as highway: α-Syn can travel from gut to brain via:
- Retrograde transport along vagus nerve
- Enteric nervous system → dorsal motor nucleus of vagus
- Brainstem → midbrain → substantia nigra
- Braak staging: α-Syn appears in enteric nerves before CNS
- Appendectomy: Associated with increased PD risk
- Constipation: Early PD symptom - gut dysfunction precedes motor symptoms
- Gut bacteria influence dopamine metabolism
- Secondary bile acids affect dopaminergic neuron survival
- L-DOPA bioavailability affected by gut microbiota
- Certain bacteria produce neurotoxic metabolites
- GABA reduction affects motor neuron excitability
- Dysbiosis activates immune cells
- Altered Th17/Treg balance
- Increased intestinal permeability
| Strain |
Mechanism |
Clinical Status |
| Lactobacillus |
GABA production, anti-inflammatory |
Phase II trials in PD |
| Bifidobacterium |
Butyrate production, barrier protection |
Phase II trials in AD |
| Faecalibacterium |
Anti-inflammatory SCFA |
Preclinical |
- Inulin-type fructans: Promote beneficial bacteria
- Resistant starch: SCFA production
- Arabinoxylan: Bifidogenic effects
- Restores microbial diversity
- Under investigation for PD and AD
- Case reports showing improvement in PD symptoms
- Mediterranean diet: Associated with reduced AD risk
- Ketogenic diet: Alters microbiome, reduces seizures
- Fiber-rich diet: Promotes SCFA production
- Polyphenol-rich foods: Antioxidant effects
- Bile acid analogs: FXR/TGR5 agonists
- SCFA supplementation: Butyrate, propionate
- LPS neutralizers: Peptidoglycan inhibitors
- Vagus nerve stimulation: Device-based approach
| Biomarker |
Source |
Disease |
Utility |
| SCFA levels |
Stool, plasma |
AD, PD |
Therapeutic monitoring |
| LPS |
Plasma, CSF |
AD, PD |
Inflammation marker |
| Bile acids |
Plasma, stool |
PD |
Dopaminergic function |
| Tryptophan metabolites |
Plasma, urine |
AD, PD |
Neurotoxicity |
| Microbiome diversity |
Stool |
All |
Diagnostic |
Microbiome dysbiosis → increased systemic inflammation → microglial activation
- SCFAs modulate NF-κB signaling
- LPS triggers TLR4-mediated inflammation
- SCFAs support mitochondrial biogenesis
- Dysbiosis impairs Complex I function
- Reduced CoQ10 synthesis from gut bacteria
- Tight junction regulation by microbiome
- LPS compromises BBB integrity
- SCFAs protect against permeability
- Autophagy regulation by SCFAs
- Gut-derived aggregates may seed brain pathology
- Proteasome function affected by microbial metabolites
- Causal inference studies: Moving beyond correlations
- Mechanistic models: Gnotobiotic mouse studies
- Microbiome-brain mapping: How specific bacteria affect brain
- Personalized medicine: Individual microbiome-based therapies
- FMT protocols: Standardization for neurodegeneration
The study of Microbiome Gut Brain Axis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Sampson TR et al. Cell. 2016;167(6):1469-1480. PMID:27984722
- Kelly JR et al. J Neurochem. 2019;151(4):461-471. PMID:30628756
- cryan JF et al. Physiol Rev. 2019;99(4):1877-2013. PMID:31460832
- Vogt NM et al. Sci Rep. 2017;7(1):13537. PMID:29051531
- Sampson TR et al. Neuron. 2020;108(1):41-53. PMID:33120197
- Chen Y et al. Front Cell Neurosci. 2022;16:840278. PMID:35177966
- Dodiya HB et al. J Exp Med. 2019;216(11):2415-2430. PMID:31350363
- Matheoud D et al. Nat Neurosci. 2019;22(5):861-872. PMID:30936559
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
50% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 32%